CIP2A is an oncoprotein overexpressed in NSCLC, and its expression is associated with poor prognosis and malignant cell proliferation.

BackgroundMetastasis is the most common cause of disease failure and mortality for non-small cell lung cancer after surgical resection. Twist has been recently identified as a putative oncogene and a key regulator of carcinoma metastasis. N-cadherin is associated with a more aggressive behavior of cell lines and tumors. The aim of this study was to evaluate the clinical relevance of Twist and N-cadherin expression in NSCLC, and the effects of Twist1 knockdown on lung cancer cells.MethodsWe examined the expressions of Twist and N-cadherin by immunohistochemistry in 120 cases of non-small cell lung cancer (including 68 cases with follow-up records). We also analyzed Twist1 and N-cadherin mRNA expression in 30 non-small cell lung cancer tissues using quantitative reverse transcription polymerase chain reaction. The functional roles of Twist1 in lung cancer cell lines were evaluated by small interfering RNA-mediated depletion of the protein followed by analyses of cell apoptosis and invasion.ResultsIn lung cancer tissues, the overexpression rate of Twist was 38.3% in lung cancer tissues. Overexpression of N-cadherin was shown in 40.83% of primary tumors. Moreover, Twist1 mRNA expression levels correlated with N-cadherin mRNA levels. Furthermore, overexpression of Twist1 or N-cadherin in primary non-small cell lung cancers was associated with a shorter overall survival (P<0.01, P<0.01, respectively). Depleting Twist expression inhibited cell invasion and increased apoptosis in lung cancer cell lines.ConclusionsThe overexpression of Twist and N-cadherin could be considered as useful biomarkers for predicting the prognosis of NSCLC. Twist1 could inhibit apoptosis and promote the invasion of lung cancer cells, and depletion of Twist1 in lung cancer cells led to inhibition of N-cadherin expression.

No abstract

The objective of the current study was to investigate the expression pattern and clinicopathological significance of SCC-S2 in patients with non-small-cell lung cancer (NSCLC). The expression profile of SCC-S2 in NSCLC tissues and adjacent noncancerous lung tissues was detected by real-time RT-PCR, western blot analysis, and immunohistochemistry. In 25 lung cancer tissues examined, 18 (72%) of them exhibited stronger levels of SCC-S2 mRNA compared with their corresponding normal tissues. SCC-S2 protein level was up-regulated in cancerous lung tissues compared to adjacent normal tissue. Moreover, the expression level of SCC-S2 in 93 archived NSCLC tissues was measured by immunohistochemical staining. SCC-S2 was found to be overexpressed in 71 of 93 (76.3%) human lung cancer samples and correlated with lymph node metastasis (P = 0.0181), p-TNM stage (P = 0.0042), Ki-67 expression (P = 0.0028), and poor survival (P = 0.012). In addition, depleting SCC-S2 expression by small-interfering RNA inhibited growth and invasion in lung cell lines. These results indicate that SCC-S2 plays an important role in NSCLC and might be a useful therapeutic target of NSCLC. (Cancer Sci 2010; 101: 1562-1569 L ung cancer is the leading cause of death among the malignant tumors worldwide, and the incidence of lung cancer is increasing. Non-small-cell lung cancer (NSCLC) is the primary histological classification of lung cancer, and the prognosis of patients with NSCLC principally correlates with tumor metastasis.(1-3) Recent molecular biology studies have revealed that many molecules affect the various biological behaviors of malignant tumors.(4-6) It is therefore considered important to clarify these pro-metastatic genes in order to improve the clinical outcome of NSCLC patients.SCC-S2 (gene symbol TNFAIP8), was originally identified in human metastatic head and neck squamous cell carcinoma (HNSCC) cell lines.(7) Its expression can be induced by tumor necrosis factor-a (TNF-a) and by activation of the transcription factor nuclear factor-kappa B (NF-jB) in various cells. (8,9) Overexpression of SCC-S2 is associated with enhanced cell survival and inhibition of activities of the apoptotic enzymes caspase-8 and caspase-3. (10)

p120-catenin, a member of the Armadillo gene family, has emerged as both a master regulator of cadherin stability and an important modulator of small GTPase activities. Therefore, it plays novel roles in tumor malignant phenotype, such as invasion and metastasis. We have reported previously that abnormal expression of p120-catenin is associated with lymph node metastasis in lung squamous cell carcinomas (SCC) and adenocarcinomas. To investigate the role and possible mechanism of p120-catenin in lung cancer, we knocked down p120-catenin using small interfering RNA (siRNA). We found that ablation of p120-catenin reduced the levels of E-cadherin and b-catenin proteins, as well as the mRNA of b-catenin. Furthermore, p120-catenin depletion inactivated RhoA, but increased the activity of Cdc42 and Rac1, and promoted proliferation and the invasive ability of lung cancer cells both in vitro and in vivo. Our data reveal that p120-catenin gene knockdown enhances the metastasis of lung cancer cells, probably by either depressing cell-cell adhesion due to lower levels of E-cadherin and b-catenin, or altering the activity of small GTPase, such as inactivation of RhoA and activation of Cdc42/Rac1. (Cancer Sci 2009; 100: 441-448)